CONNECT WITH US
HealthTech

HealthTech

Senseonics Doses First Human in Trial of Freedom Fully Implantable One-Year CGM

HIT Consultant logo

Published on

Add as a preferred source on Google
Senseonics Doses First Human in Trial of Freedom Fully Implantable One-Year CGM

Freedom is engineered to transmit real-time interstitial glucose telemetry directly to a user’s mobile device via integrated Bluetooth Low Energy (BLE), completely eliminating the need for any exterior, on-body transmitter.

The clinical challenge of eliminating an on-body transmitter from an implantable biosensor centers on two core constraints: micro-battery chemistry and RF signal attenuation through biological tissue. Historically, external transmitters served double duty—supplying inductive power to the passive subcutaneous sensor while broadcasting Bluetooth signals through open air to a smartphone.

Freedom retains the core optical, fluorescence-based glucose-sensing chemistry and one-year operational lifespan validated in Eversense 365, while integrating miniaturized active electronics directly into the sub-dermal capsule:

The first-in-human trial is an early feasibility study designed to evaluate basic clinical safety, biological tissue tolerance, and device functionality—specifically real-world BLE packet delivery through human dermis and adipose layers.

The human trial follows pre-clinical animal studies completed during the second quarter of 2026, which tested multiple antenna geometries and anatomical implantation depths. Over approximately seven weeks of continuous logging and more than 18,500 communication data points, the selected antenna configuration achieved a 100% communication success rate within target operational ranges.

Dr. Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics, outlined the commercial thesis: “Now being tested in humans for the first time, the Freedom CGM represents our vision to eliminate the requirement for an on-body component, effectively making continuous glucose monitoring invisible. We believe this represents an extremely attractive proposition for millions of people with diabetes and we are proudly leading the race to get there.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.